Vocal hyperfunction (VH) is associated with the most frequently occurring types of voice disorders including benign vocal fold lesions (e.g., nodules) and dysphonia that occurs in the absence of concurrent pathology (e.g., muscle tension dysphonia). In 1989, Hillman et al. (J. Speech Hear. Res. 32, 373–392, 1989) proposed and initially validated the first experimental framework for hyperfunctional voice disorders that was based on using objective measures of vocal function to test basic concepts about VH. This initial work set the stage for a program of research aimed at improving the prevention, diagnosis, and treatment of hyperfunctional voice disorders by attaining a better understanding of the etiological and pathophysiological mechanisms that underlie specific disorders within the broad range of those associated with VH. An update on the progress of this ongoing work will be provided including new insights gained through the use of ambulatory voice monitoring, machine learning, and computer modeling of phonatory mechanisms. [Work supported by NIH-NIDCD R33 DC011588 and the Voice Health Institute.]